ES2146668T3 - Defensinas liposomicas. - Google Patents

Defensinas liposomicas.

Info

Publication number
ES2146668T3
ES2146668T3 ES94932006T ES94932006T ES2146668T3 ES 2146668 T3 ES2146668 T3 ES 2146668T3 ES 94932006 T ES94932006 T ES 94932006T ES 94932006 T ES94932006 T ES 94932006T ES 2146668 T3 ES2146668 T3 ES 2146668T3
Authority
ES
Spain
Prior art keywords
defensins
treatment
release
liposomes
liposomic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94932006T
Other languages
English (en)
Inventor
Andrew S Janoff
Walter Perkins
Imran Ahmad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Application granted granted Critical
Publication of ES2146668T3 publication Critical patent/ES2146668T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

LAS DEFENSINAS SON COMPONENTES DE PROTEINAS CITOTOXICAS, TUMORICIDAS, MICROBICIDAS DE SISTEMAS DE DEFENSA DE ANFITRIONES ANIMALES. PUEDEN ESTAR ATRAPADAS EN LIPOSOMAS QUE CONTENGAN UN LIPIDO DE INHIBICION DE LA LIBERACION DE MANERA QUE LAS DEFENSINAS ESTEN NEUTRALIZADAS, Y SE INHIBA SU LIBERACION DE LOS LIPOSOMAS. DE CUALQUIER MODO, LAS DEFENSINAS PERMANECEN ACTIVAS CUANDO SE EXPONEN A UN MATERIAL ENDOCITOSADO EN VESICULAS ENDOCITICAS. LAS FORMULACIONES DE DEFENSINAS LIPOSOMIALES SE ADMINISTRAN A ANIMALES PARA EL TRATAMIENTO O PREVENCION DE LAS INFECCIONES MICROBIANAS, PARA EL TRATAMIENTO DE CANCERES Y PARA EL TRATAMIENTO DE ENFERMEDADES CARACTERIZADAS POR UNA DEFICIENCIA DE LA ACTIVIDAD CITOTOXICAS INTERMEDIADAS POR LAS PROTEINAS EN LOS GRANULOS CITOPLASMATICOS.
ES94932006T 1993-10-25 1994-10-25 Defensinas liposomicas. Expired - Lifetime ES2146668T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14269193A 1993-10-25 1993-10-25

Publications (1)

Publication Number Publication Date
ES2146668T3 true ES2146668T3 (es) 2000-08-16

Family

ID=22500893

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94932006T Expired - Lifetime ES2146668T3 (es) 1993-10-25 1994-10-25 Defensinas liposomicas.

Country Status (13)

Country Link
US (1) US5766624A (es)
EP (1) EP0725629B1 (es)
JP (1) JP4076026B2 (es)
KR (1) KR960704524A (es)
AT (1) ATE193203T1 (es)
AU (1) AU680702B2 (es)
CA (1) CA2172955C (es)
DE (1) DE69424680T2 (es)
DK (1) DK0725629T3 (es)
ES (1) ES2146668T3 (es)
GR (1) GR3034259T3 (es)
PT (1) PT725629E (es)
WO (1) WO1995011670A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6984622B2 (en) * 1998-03-25 2006-01-10 The Regents Of The University Of California Use of lipopolysaccharides to manage corneal infections and wounds
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
WO2002009738A1 (en) * 2000-07-28 2002-02-07 Murphy Christopher J Transplant media
US6782459B1 (en) * 2000-08-14 2004-08-24 Rambus, Inc. Method and apparatus for controlling a read valid window of a synchronous memory device
AU2002240137A1 (en) * 2001-01-30 2002-08-12 University Of Iowa Research Foundation Antiviral activities of primate theta defensins and mammalian cathelicidins
US7550558B2 (en) * 2001-06-01 2009-06-23 Fundacao De Ampara A Pesquiso Do Estado De Sao Paolo (Fapesp) Antimicrobial peptides and methods for identifying and using such peptides
US6924052B2 (en) 2002-04-24 2005-08-02 General Motors Corporation Coolant flow field design for fuel cell stacks
US6866955B2 (en) 2002-05-22 2005-03-15 General Motors Corporation Cooling system for a fuel cell stack
US20060115480A1 (en) * 2002-12-19 2006-06-01 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
CA2526878A1 (en) * 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
US20060008466A1 (en) * 2004-07-07 2006-01-12 University Of Saskatchewan Methods for treating and preventing microbial infections
US20060263663A1 (en) * 2005-05-19 2006-11-23 Fowler Sitima R Temperature management of an end cell in a fuel cell stack
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US9044438B2 (en) 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
DE102005031206A1 (de) * 2005-07-01 2007-01-11 Rovi Gmbh & Co. Kosmetische Rohstoffe Kg Verfahren zur Untersuchung von Liposomen
WO2010048572A1 (en) * 2008-10-23 2010-04-29 Cornell University A novel anti-viral method
GB0821687D0 (en) 2008-11-28 2008-12-31 Secr Defence Peptides
GB0821707D0 (en) * 2008-11-28 2008-12-31 Secr Defence Peptides
CA2772036A1 (en) * 2009-08-24 2011-03-03 Phigenix, Inc. Targeting pax2 for the treatment of breast cancer
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
PT3389620T (pt) * 2015-12-15 2022-12-05 Medicell Tech Llc Composições de estimulação de células estaminais e métodos de tratamento de melasma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (es) * 1977-08-05 1981-02-13 Battelle Memorial Institute
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5030453A (en) * 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US5169637A (en) * 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4975282A (en) * 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4981690A (en) * 1987-10-27 1991-01-01 Board Of Regents, The University Of Texas System Liposome-incorporated mepartricin
US5032574A (en) * 1988-05-26 1991-07-16 Invitron Corporation Novel antimicrobial peptide
US4962277A (en) * 1988-12-09 1990-10-09 Scripps Clinic And Research Foundation Deletion analogues of magainin peptides
WO1991004019A1 (en) * 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5045531A (en) * 1989-12-18 1991-09-03 Magainin Sciences Inc. Wound treatment employing biologically active ion channel forming peptides and proteins
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells

Also Published As

Publication number Publication date
JPH09504298A (ja) 1997-04-28
EP0725629B1 (en) 2000-05-24
AU680702B2 (en) 1997-08-07
AU8088894A (en) 1995-05-22
CA2172955C (en) 2002-12-24
PT725629E (pt) 2000-11-30
CA2172955A1 (en) 1995-05-04
US5766624A (en) 1998-06-16
GR3034259T3 (en) 2000-12-29
ATE193203T1 (de) 2000-06-15
DE69424680T2 (de) 2000-09-28
JP4076026B2 (ja) 2008-04-16
KR960704524A (ko) 1996-10-09
WO1995011670A1 (en) 1995-05-04
DK0725629T3 (da) 2000-08-07
DE69424680D1 (de) 2000-06-29
EP0725629A1 (en) 1996-08-14

Similar Documents

Publication Publication Date Title
DK0725629T3 (da) Liposomale defensiner
WO1996041623A3 (en) Tricot-like pouch for the delivery of topical drugs and cosmetics
FI963696A0 (fi) Geeli ihosairauksien hoitoon ja ihon desinfiointiin
ATE200025T1 (de) Flüssige arzneizubereitungen enthaltend schilddrüsenhormone
DE69314339D1 (de) Auf proteinbasis beruhendes liefersystem
IL122248A (en) Use of nisin in the manufacture of a medicament for the treatment of an infection and pharmaceutical compositions comprising nisin for said treatment
BG103552A (bg) Терапевтични средства
EP0225130A3 (en) Liposome composition
EP0850068A4 (en) LIPID EXTRACTS WITH ANTI-INFLAMMATORY ACTIVITY
CA2151604A1 (fr) Application du riluzole dans le traitement de lesions neurologiques liees a des traumatismes
AU8335291A (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals
CA2045885A1 (en) Inhibition of mammalian muscle wasting and protein degradation by tetracyclines
ES2180629T3 (es) Usos terapeuticos de productos dimeros de proteina bactericida/aumentadora de la permeabilidad.
MX9602973A (es) Uso de un antagonista de bradiquinina en una composicion, cosmetica, farmaceutica o dermatologica y la composicion obtenida.
TR200101633T2 (tr) Farmasötik bileşim
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
Pak et al. Liposomal delivery of biological response modifiers to macrophages
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
JP2000319171A (ja) 殺菌性皮膚外用剤組成物
Chatterjee et al. Litomosoides carinii in rodents: immunomodulation in potentiating action of diethylcarbamazine
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
AU3439897A (en) Pharmaceutical formulations containing colostrum and their use
Mielach Selective toxicity to intra-and extracellular bovine Staphylococcus aureus by penicillin encapsulated in immunoliposomes: A model system.
Mezinova et al. Effect of anti-chlamydial drugs on the effectiveness of the treatment of habitual abortion

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 725629

Country of ref document: ES